To study exenatide's efficacy in reducing hyperglycemia and improving neurologic outcomes, researchers developed the phase 2, international, multicenter, randomized controlled TEXAIS trial.

The launch of exenatide once weekly is crucial to Amylin but the company has not yet made a decision on whether it will extend the "Byetta" brand name to the new drug.

Exenatide, or Byetta, is a synthetic peptide that acts at the receptor for GLP-1 – a hormone that is made in the gastrointestinal track that stimulates insulin secretion and also decreases the ...

The FDA approved the once-weekly version of exenatide for type 2 diabetes with a list of required postmarketing studies on the potential for cardiovascular events and medullary thyroid carcinoma.

Exenatide is a GLP-1-like (analog) medication primarily prescribed to treat Type 2 diabetes, approved by the U.S. Food and Drug Administration in 2005.

Exenatide is a GLP-1 agonist. Co-lead author on the new study, Tom Foltynie, says these findings certainly help add weight to the link between type 2 diabetes and Parkinson’s disease.

New data suggest Vivani’s miniature exenatide implant, NPM-115, works as well as Novo Nordisk’s Wegovy and Ozempic for weight loss in mice. The implant delivers high doses of exenatide, a GLP ...

The median age was 60 years (range, 43 to 72) in the 27 patients for whom age was noted. Nineteen patients (63%) were women. The median dose of exenatide (reported for 25 of the 30 patients) was ...

Individuals who received exenatide lost more weight in 24 weeks than controls did, the authors reported. Those who received the medication lost an average of more than 11 pounds (5.06 kg), whereas ...

Vivani Medical unveils preclinical data on NPM-115, a twice-yearly exenatide subdermal implant for weight loss. Achieving a 20% reduction in high-fat diet-induced obese mice, comparable to Novo ...

References: Vijiaratnam N, Girges C, Auld G, et. al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: a phase 3 ...

The FDA approved exenatide in April 2005 and it was the first incretin mimetic to hit the market. Exenatide (Byetta, Amylin) is synthetic exendin-4, which binds to and activates the pancreatic ...